Genotype | Patients n (%) | Controls n ( %) | p-value or (95 % CI) |
---|---|---|---|
-1306CC | 22 (75.86) | 27 (48.21) | 0.0170٭ |
-1306TC and -1306TT | 7 (24.14) | 29 (51.79) | 0.2962 (0.1091-0.8045) |
Genotype | Patients n (%) | Controls n (%) | P-value OR (95 % CI) patients vs. control * |
---|---|---|---|
-1306CC | 53 (67.1) | 27 (48) | 0.028 |
-1306CT | 24 (30.4) | 25 (45) | 0.457 (0.226-0.932) |
-1306TT | 2 ( 2.5) | 4 (7) | |
-1562CC | 56 (71) | 40 (71) | 0.945 |
-1562CT | 20 (25) | 16 (29) | 1.27 (0.482-2.187) |
-1562TT | 3 (4) | 0 (0) |
Variable | Values |
---|---|
Age, mean± SD | 61.4 ± 7.3 |
Gender, male n (%) female n ( %) | 65 (63.7) 37 (36.3) |
Smokers, n (%) | 23 (22.5) |
Diabetes duration, mean± SD | 10.1±5.8 |
BMI, mean± SD | 28.8±4.8 |
HbA1c, mean± SD | 9.40±2.22 |
FBG, mean± SD | 6.90±1.94 |
Total cholesterol (mmol/l), mean± SD | 5.20±1.35 |
LDLc (mmol/l), mean± SD | 3.11±1.03 |
HDLc (mmol/l), mean± SD | 1.15±0.30 |
Triglycerides (mmol/l), mean± SD | 2.25±1.16 |
Albumin mg/24h/urine, mean± SD | 12.54±2.79 |
Serum creatinine (μmol/l), mean± SD | 87.81±42.75 |
OAD only, n (%) | 23 (22.5) |
Insulin only, n (%) | 14 (13.7) |
OAD + insulin, n (%) | 65 (63.7) |
Metformin, n (%) | 88 (86.3) |
Retinopathy non-proliferative, n (%) | 21 (20.6) |
Retinopathy proliferative, n (%) | 9 (8.8) |
Polyneuropathy, n (%) | 40 (39.2) |
Nephropathy, n (%) | 11 (10.8) |